Fas、FasL蛋白在肺癌组织中的表达及临床意义

Expression of Fas and FasL proteins in lung cancer tissues and their clinical significance

目的探讨Fas、Fas L蛋白在肺癌组织中的表达及临床意义。方法应用免疫组化SP法检测89例原发性肺癌组织、12例淋巴结转移性肺癌组织、12例肺癌癌前病变组织和10例正常肺组织中Fas、Fas L蛋白表达情况。分析各指标间相关性及其与肺癌临床病理参数的关系。结果与对照组比较,Fas和Fas L在其他3组中表达差异显著(P<0.05)。Fas在肺癌细胞中主要分布于细胞质,而正常肺组织主要表达于细胞膜,Fas在非小细胞肺癌(NSCLC)中的阳性率高于小细胞肺癌(SCLC)(P<0.05),Fas L与肺癌的临床分期、淋巴结转移有关(P<0.05),Fas与Fas L呈负相关(P<0.05)。结论 Fas、Fas L蛋白的异常表达在肺癌的恶性发展中起重要作用,二者在肺癌的发生、发展、侵袭转移中起协同作用。

Objective To detect the expression of Fas and FasL in lung cancer tissues by immunohistochemistry and to discuss their roles in lung cancer pathogenesis and progression. Methods The expression of Fas and FasL was detected in 89 primary lung cancer tissues, 12 premaliganant lesions, 12 lymph node metastases, and 10 normal lung tissues as the control by immunohistochemical method. Results Fas protein was detected in 75% , 62. 9% and 41.7% of primary lung cancer tissues, premalignant lesions and lymph node metastases, respectively; there was significant difference among the three groups （P 〈 0.05）. FasL protein was detected in 41.7% , 53.9% and 75% of primary lung cancer tissues, premalignant lesions and lymph node metastases, respectively, which were negatively correlated with that of Fas （ P 〈 0. 05 ）. The positive rate of Fas was significantly lower in SCLC than NSCLC （ P 〈 0. 05 ） ; that of FasL was higher in the group of stage Ⅲ＋ Ⅳthan stage Ⅰ ＋ Ⅱ （ P 〈 0. 05）, and it was higher in the group with lymph node metastasis than that without lymph node metastasis （P 〈 0. 05 ）. Conclusion Abnormal expression of Fas/FasL plays an importment cooperative role in the development, progress, invasion and metastasis of lung cancer.